"FDA Approves Symtuza For Treatment Of HIV Infection" - Troy Brown, RN
The US Food and Drug Administration (FDA) has approved what its manufacturer calls "the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naive and certain virologically suppressed adults." Using the brand name Symtuza and made by Janssen Pharmaceuticals, the drug combo combines the proven high barrier to resistance of darunavir with a formulation designed for improved tolerability and the convenience of an STR. "The approval of Symtuza…will provide patients with yet another one-tablet regimen with excellent potency, tolerability, and a high genetic barrier to resistance,” said Antonio Urbina, MD, associate professor of medicine and infectious diseases at the Icahn School of Medicine at Mount Sinai. "At the Institute for Advanced Medicine at Mount Sinai, it will become one of our antiviral options for our immediate start program, which provides same-day HIV treatment to patients newly diagnosed with HIV," he added.
- Antonio Urbina, MD, Associate Professor, Medicine, Infectious Disease, Medical Director, Institute for Advanced Medicine, Icahn School of Medicine at Mount Sinai